Thalidomide Finds Redemption as a Cancer Foe
WebMD News Archive
Nov. 17, 1999 (Seattle) -- Thalidomide, a drug best known for causing horrific birth defects, is prolonging the lives of people with a rare form of cancer, according to a study in TheNew England Journal of Medicine Thursday.
The study, conducted by a team at the University of Arkansas for Medical Sciences in Little Rock, found that thalidomide helped a third of people with advanced multiple myeloma, an incurable cancer of the bone marrow. Most of the people in the Arkansas study had exhausted all other treatment options before they got the drug.
One of the researchers, Bart Barlogie, MD, PhD, tells WebMD that the results represent "a milestone in therapy for myeloma." Barlogie, an internationally known expert on the disease, says the prospect of a new weapon to fight it is exciting because doctors have been using the same two drugs for about 40 years.
Multiple myeloma strikes nearly 14,000 people a year in the U.S. More than 70% of them die within five years. Thalidomide is a drug that was widely used in Europe to prevent morning sickness in pregnant women. It was pulled off the market after reports that it led to severe birth defects, including children with flipper-like arms and legs. In recent years, though, thalidomide has made a comeback as a treatment for leprosy.
In the new study, researchers gave increasing doses of thalidomide to 84 people with multiple myeloma who were failing other treatments. Most were getting sicker despite having received the highest possible doses of chemotherapy -- usually the final treatment option.
But despite the advanced stage of their disease, about one-third of the patients got better with thalidomide. Tests that indicate the presence of cancerous cells in the bone marrow showed dramatic reductions for about 10% of the patients, including two who had a complete remission. Barlogie says it's not clear yet how long the benefits last.
In an editorial about the study, two cancer researchers from Harvard Medical School called the results "remarkable." One of the researchers, Kenneth Anderson, MD, tells WebMD that thalidomide is generating huge excitement in the medical community because multiple myeloma has proven so difficult to treat.